Therapeutic agent for chronic obstructive pulmonary disease and method for treating chronic obstructive pulmonary disease using the same

Abstract

This therapeutic agent for chronic obstructive pulmonary disease comprises, an active ingredient, at least one of a 7-aminoquinolinone derivative represented by the general formula (I): wherein R 1 represents a hydrogen atom or an alkyl group; R 2 and R 3 each represents a group selected from a hydrogen atom, an acyl group, an alkyl group and an alkenyl group; and R 4 and R 5 each represents a group selected from a hydrogen atom, an acyl group, an alkyl group, an alkenyl group and an aralkyl group, and its physiologically acceptable salt.

1 . A therapeutic agent for chronic obstructive pulmonary disease comprising, as an active ingredient, at least one of a 7-aminoquinolinone derivative represented by the general formula (I): 
       
         
           
           
               
               
           
         
         wherein R 1  represents a hydrogen atom or an alkyl group; R 2  and R 3  each represents a group selected from a hydrogen atom, an acyl group, an alkyl group and an alkenyl group; and R 4  and R 5  each represents a group selected from a hydrogen atom, an acyl group, an alkyl group, an alkenyl group and an aralkyl group, and its physiologically acceptable salt. 
       
     
     
         2 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 1 , wherein R 1  represents a hydrogen atom, or a linear or branched alkyl group having 1 to 10 carbon atoms. 
     
     
         3 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 1 , wherein R 2  and R 3  each represents a hydrogen atom, an acyl group, a linear or branched alkyl group having 1 to 10 carbon atoms, or a linear or branched alkenyl group having 2 to 10 carbon atoms. 
     
     
         4 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 1 , wherein R 4  and R 5  each represents a hydrogen atom, an acyl group, a linear or branched alkyl group having 1 to 10 carbon atoms, a linear or branched alkenyl group having 2 to 10 carbon atoms, or an aralkyl group. 
     
     
         5 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 1 , wherein R 1  represents a hydrogen atom, or a linear or branched alkyl group having 1 to 10 carbon atoms; R 2  and R 3  each represents a hydrogen atom, an acyl group, a linear or branched alkyl group having 1 to 10 carbon atoms, or a linear or branched alkenyl group having 2 to 10 carbon atoms; and R 4  and R 5  each represents a hydrogen atom, an acyl group, a linear or branched alkyl group having 1 to 10 carbon atoms, a linear or branched alkenyl group having 2 to 10 carbon atoms, or an aralkyl group. 
     
     
         6 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 5 , wherein R 2  represents a hydrogen atom, and R 3  represents a linear or branched alkyl group having 1 to 10 carbon atoms, or linear or branched alkenyl group having 2 to 10 carbon atoms. 
     
     
         7 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 5 , wherein R 2  represents a linear or branched alkyl group having 1 to 10 carbon atoms, or a linear or branched alkenyl group having 2 to 10 carbon atoms, and R 3  represents a hydrogen atom. 
     
     
         8 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 6 , wherein R 4  represents a hydrogen atom, and R 5  represents a hydrogen atom, an acyl group, a linear or branched alkyl group having 1 to 10 carbon atoms, a linear or branched alkenyl group having 2 to 10 carbon atoms, or an aralkyl group. 
     
     
         9 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 8 , wherein R 5  represents an acyl group. 
     
     
         10 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 9 , wherein R 5  represents an acyl group comprising a cinnamoyl group which may have a substituent. 
     
     
         11 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 10 , wherein R 5  represents a 4-hydroxy-3-methoxycinnamoyl group or a 3,5-dimethoxy-4-hydroxycinnamoyl group. 
     
     
         12 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 1 , wherein the chronic obstructive pulmonary disease is chronic bronchitis. 
     
     
         13 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 1 , wherein the chronic obstructive pulmonary disease is pulmonary emphysema. 
     
     
         14 . Use of the therapeutic agent for chronic obstructive pulmonary disease according to  claim 1  for treating chronic obstructive pulmonary disease. 
     
     
         15 . A method for treating chronic obstructive pulmonary disease, which comprises using the therapeutic agent for chronic obstructive pulmonary disease according to  claim 1 . 
     
     
         16 . Use of at least one of a 7-aminoquinolinone derivative represented by the general formula (I); 
       
         
           
           
               
               
           
         
         wherein R 1  represents a hydrogen atom or an alkyl group; R 2  and R 3  each represents a group selected from a hydrogen atom, an acyl group, an alkyl group and an alkenyl group; and R 4  and R 5  each represents a group selected from a hydrogen atom, an acyl group, an alkyl group, an alkenyl group and an aralkyl group, and its physiologically acceptable salt, for preparing a therapeutic agent for chronic obstructive pulmonary disease. 
       
     
     
         17 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 7 , wherein R 4  represents a hydrogen atom, and R 5  represents a hydrogen atom, an acyl group, a linear or branched alkyl group having 1 to 10 carbon atoms, a linear or branched alkenyl group having 2 to 10 carbon atoms, or an aralkyl group. 
     
     
         18 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 17 , wherein R 5  represents an acyl group. 
     
     
         19 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 18 , wherein R 5  represents an acyl group comprising a cinnamoyl group which may have a substituent. 
     
     
         20 . The therapeutic agent for chronic obstructive pulmonary disease according to  claim 19 , wherein R 5  represents a 4-hydroxy-3-methoxycinnamoyl group or a 3,5-dimethoxy-4-hydroxycinnamoyl group.